IMpassione031、IMpassion030
いずれもEFS利益は示せなかった。
アジュバントだけの030試験は11%のイベントだけで、途中中止。
本当にKN 522のアジュバント必要？という質問はもっともですが、本結果だけだとなんとも言えずSWOG S1418/NRG BR006がネガティブだとまた少し趣きが違います。 #SABCS23

《決算発表より》
【トリプルネガティブ乳がん：術前・術後治療】「テセントリク」の有用性を検証するPhase3試験『IMpassion030』を開始。

🎥 New Episode Alert! Dr Kevin Punie & Prof Evandro de Azambuja, MD, PhD discuss the NeoTRIP & IMpassion030 trials on TNBC treatments in Ep 14 of '𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿'. Discover the latest insights into TNBC therapies.

No benefit from adding atezolizumab to adjuvant chemotherapy with weekly paclitaxel and ddEC in TNBC patients undergoing primary surgery from ALEXANDRA/IMpassion030 trial #SABCS23 #BreastCancer

Alexandra/IMpassion030 is actively accruing! A great opportunity for TNBC patients to participate in this trial evaluating adjuvant atezolizumab.

Final analysis results from the ALEXANDRA/Impassion030 phase 3 trial in #TNBC patients presented by Heather McArthur, MD, MPH at #EBCC14
Michail ignatiadis OncoAlert European Breast Cancer Conference (EBCC-14) #immunotherapy #breastcancer

Discover key insights from #SABCS2023 with
Prof Francois Duhoux and Prof Michail Ignatiadis discussing the ALEXANDRA/IMpassion030 trial. Learn about the latest advancements in treating TNBC. medimix.be/onco/results-o…
#BreastCancerAwareness #MediMix #OncologyResearch

#SABCS23
#IMpassion030
Adding #atezolizumab to adjuvant chemotherapy does not improve EFS in stage 2/3 #TNBC ⁦Michail ignatiadis⁩
⁦OncoAlert⁩ ⁦SABCS⁩ ⁦EORTC Breast Cancer Group⁩

Impassion030 #SABCS23
Stage II/III TNBC w/ surgery upfront
I) iDFS ITT (II iDFS PDL1, N+, OS, RFI)

🕵🏼‍♀️addition of Atezolizumab in adjuvant CT for TNBC not supported. Still ongoing translational research
✅Improved knowledge of implementation of IO in algorithm for eTNBC

👇🏻👇🏻

Presenting #IMpassion030 at #ESMO19 #ESMO2019 with friend and colleague Michail ignatiadis. Terrific collaboration!!

ALEXANDRA/IMpassion030 phase 3 trial presented by Michail ignatiadis

The addition of atezolizumab to adjuvant chemo does not
improve iDFS in pts with stage II-III TNBC

Very proud to be part of this effort!

BIG against BC
Institut Jules Bordet Instituut
Alliance for Clinical Trials in Oncology
OncoAlert
#SABCS23

Do not miss the ALEXANDRA/IMpassion030 poster at the OT session today presented by Michail ignatiadis - A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early TNBC #SABC2018 BIG against BC Alliance for Clinical Trials in Oncology Institut Jules Bordet Instituut

#SABCS23 - ICI for early-stage BC:

CK-7FL (nivo) and KN756 (pembro) - for HR+BC, higher pCR benefit of neoadj ICI in higher PD-L1+ and lower ER expression.

Alexandra/IMpassion030 - no benefit of adjuvant atezo for stage II-III TNBC - reinforces the use of neoadj ICI!

Final results of the ALEXANDRA/IMpassion030 trial presented by Heather McArthur, MD, MPH at #EBCC14

No benefit from the adition of atezolizumab to adjuvant chemotherapy in pts with TNBC

Incredible honor to have been part of this important trial!

Michail ignatiadis Shigehira Saji OncoAlert
#bcsm

ALEXANDRA/IMpassion030 was present in #ASC019 and is actively recruiting in 22 countries: A phase 3 study of adjuvant chemotherapy with or without atezolizumab in patients with operable triple negative #BreastCancer BIG against BC Alliance for Clinical Trials in Oncology #OncoAlert

No benefit from adding adjuvant Atezo to adj chemo in stage II-III TNBC. ALEXANDRA/IMpassion030 trial presented at #SABCS23 .

Can't wait the results from trials of adjuvant immuno in TNBC not achieving pCR, maybe results will be different with better patients selection.

Excited to be presenting the final analysis of #IMpassion030 /ALEXANDRA at #EBCC14 in Milan today!! An important #TNBC study and a tremendous collaboration!!

Phase 3 ALEXANDRA/IMpassion030 trial, HR for iDFS in the ITT population (primary endpoint) crossed the pre-specified futility boundary (HR>1), HR 1.12 [0.87-1.45].

The addition of atezolizumab to adjuvant chemotherapy is not the optimal timing or ICI partner #SABCS23

#ScienceLink #SABCS2023 #ALEXANDRA #IMpassion030
Cruzar el límite predefinido de futilidad con HR >1 indica que es muy improbable que atezolizumab adyuvante mejore la SLEi cuando se agrega a la QT en pacientes con CMTN en estadios tempranos

shorturl.at/hknr2

Part of the BIG HQ ALEXANDRA/IMpassion030 team at the APAC investigator’s meeting in Bangkok. ALEXANDRA is a Ph III Adjuvant Study Comparing Atezolizumab With or without Chemo In TNBC. This trial is a collaboration between BIG against BC, Alliance for Clinical Trials in Oncology, Institut Jules Bordet Instituut, FS and Roche